Two Sigma Investments LP Has $2.46 Million Holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)

Two Sigma Investments LP raised its stake in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) by 77.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 651,517 shares of the company's stock after buying an additional 284,280 shares during the quarter. Two Sigma Investments LP owned about 0.95% of Amylyx Pharmaceuticals worth $2,463,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in AMLX. Blue Trust Inc. lifted its position in Amylyx Pharmaceuticals by 232.1% in the 4th quarter. Blue Trust Inc. now owns 6,987 shares of the company's stock valued at $26,000 after acquiring an additional 4,883 shares in the last quarter. Fox Run Management L.L.C. acquired a new stake in shares of Amylyx Pharmaceuticals in the 4th quarter valued at about $45,000. Alpine Global Management LLC bought a new stake in shares of Amylyx Pharmaceuticals in the fourth quarter valued at about $45,000. RPO LLC bought a new stake in shares of Amylyx Pharmaceuticals in the fourth quarter valued at about $46,000. Finally, EntryPoint Capital LLC acquired a new position in shares of Amylyx Pharmaceuticals during the fourth quarter worth about $53,000. Institutional investors and hedge funds own 95.84% of the company's stock.

Insider Buying and Selling

In other Amylyx Pharmaceuticals news, Director Bernhardt G. Zeiher bought 10,000 shares of the business's stock in a transaction that occurred on Thursday, March 20th. The shares were acquired at an average cost of $3.70 per share, for a total transaction of $37,000.00. Following the transaction, the director now directly owns 10,000 shares in the company, valued at approximately $37,000. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO James M. Frates sold 10,896 shares of Amylyx Pharmaceuticals stock in a transaction on Monday, March 31st. The stock was sold at an average price of $3.47, for a total transaction of $37,809.12. Following the transaction, the chief financial officer now owns 290,988 shares in the company, valued at approximately $1,009,728.36. This trade represents a 3.61% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 44,811 shares of company stock worth $155,494 in the last ninety days. 11.70% of the stock is owned by insiders.

Amylyx Pharmaceuticals Stock Down 3.9%

Shares of NASDAQ:AMLX traded down $0.20 during midday trading on Wednesday, hitting $4.92. The stock had a trading volume of 536,561 shares, compared to its average volume of 1,206,059. The company's 50-day moving average price is $4.51 and its 200-day moving average price is $4.15. Amylyx Pharmaceuticals, Inc. has a fifty-two week low of $1.58 and a fifty-two week high of $7.27. The company has a market capitalization of $438.57 million, a P/E ratio of -1.29 and a beta of -0.60.

Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.42) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.03. Research analysts expect that Amylyx Pharmaceuticals, Inc. will post -2.2 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

AMLX has been the topic of several research reports. Leerink Partnrs upgraded Amylyx Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, May 6th. Mizuho increased their target price on shares of Amylyx Pharmaceuticals from $7.00 to $8.00 and gave the stock an "outperform" rating in a report on Wednesday, May 14th. TD Cowen started coverage on shares of Amylyx Pharmaceuticals in a research note on Friday, May 30th. They issued a "buy" rating on the stock. Leerink Partners upgraded shares of Amylyx Pharmaceuticals from a "market perform" rating to an "outperform" rating and increased their price objective for the stock from $4.00 to $10.00 in a research note on Wednesday, May 7th. Finally, HC Wainwright raised their price objective on Amylyx Pharmaceuticals from $12.00 to $16.00 and gave the company a "buy" rating in a report on Friday, May 9th. One research analyst has rated the stock with a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat.com, Amylyx Pharmaceuticals presently has a consensus rating of "Buy" and an average price target of $9.83.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.